Study of Transthyretin Amyloidosis in Patients 65 and Older with Heart Failure and Normal Heart Pump Function

What this Trial Is About

Researchers are studying transthyretin amyloidosis ATTR in patients aged 65 and older who have Heart Failure with Preserved Ejection Fraction HFpEF, a type of heart failure where the hearts pumping function is normal. This single-center diagnostic study aims to find out how often ATTR occurs in these heart failure patients and to improve methods for predicting which patients may have transthyretin amyloidosis. Early identification of amyloidosis could help patients start treatment sooner. Participants will undergo a single study visit during which they will receive a 99mTc-pyrophosphate SPECT scan, a nuclear imaging test used to detect cardiac amyloidosis. Additional procedures include blood and optional DNA sample collection, questionnaires about neuropathy, carpal tunnel syndrome, frailty, and heart failure symptoms, a 6-minute walk test, electrocardiogram ECG, and echocardiogram. The study focuses on patients without a prior diagnosis of amyloidosis and involves no placebo or drug interventions. Throughout the study, researchers will review participants electronic health records for up to 5 years to assess hospitalizations and survival. Clinical outcomes of interest include days spent alive outside the hospital due to heart failure hospitalizations, presence of autonomic neuropathy, carpal tunnel syndrome, and polyneuropathy. The main outcome measured is the diagnosis of ATTR by the 99mTc-pyrophosphate scan on the day of the study visit. This comprehensive evaluation will help better understand symptoms and the prevalence of ATTR in heart failure patients.

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF